Rhenman & Partners Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-65,000	Closed	-$6.41M	–	95
2021 Q1	$6.41M	Buy	65,000 +2,500	+4%	+$300K	0.45%	64
2020 Q4	$6.78M	Hold	62,500	–	–	0.55%	57
2020 Q3	$6.44M	Buy	62,500 +12,500	+25%	+$1.87M	0.57%	56
2020 Q2	$10.4M	Sell	50,000 -5,000	-9%	-$886K	1.13%	37
2020 Q1	$5.37M	Sell	55,000 -10,000	-15%	-$1.17M	0.75%	52
2019 Q4	$7.49M	Buy	65,000 +53,033	+443%	+$4.67M	0.82%	52
2019 Q3	$652K	Hold	11,967	–	–	0.08%	80
2019 Q2	$1.42M	Hold	11,967	–	–	0.16%	73
2019 Q1	$627K	Hold	11,967	–	–	0.07%	76
2018 Q4	$377K	Sell	11,967 -3,430	-22%	-$140K	0.04%	78
2018 Q3	$931K	Hold	15,397	–	–	0.09%	71
2018 Q2	$816K	Buy	15,397 +2,696	+21%	+$162K	0.08%	73
2018 Q1	$737K	Hold	12,701	–	–	0.09%	75
2017 Q4	$445K	Sell	12,701 -2,700	-18%	-$88.8K	0.06%	88
2017 Q3	$562K	Hold	15,401	–	–	0.07%	82
2017 Q2	$385K	Hold	15,401	–	–	0.06%	94
2017 Q1	$416K	Hold	15,401	–	–	0.07%	88
2016 Q4	$447K	Hold	15,401	–	–	0.09%	88
2016 Q3	$633K	Hold	15,401	–	–	0.1%	90
2016 Q2	$487K	Hold	15,401	–	–	0.09%	92
2016 Q1	$796K	Hold	15,401	–	–	0.16%	88
2015 Q4	$1.47M	Hold	15,401	–	–	0.22%	91
2015 Q3	$1.27M	Hold	15,401	–	–	0.2%	89
2015 Q2	$2.5M	Buy	15,401 +11,101	+258%	+$3.75M	0.3%	89
2015 Q1	$1.74M	Buy	+4,300	New	+$1.82M	0.29%	84

Other funds holding ADVM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rhenman & Partners Asset Management's ADVM Position: Q2 2021 in Review

Rhenman & Partners Asset Management sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 65,000 shares — an estimated $6.41M sold.

Rhenman & Partners Asset Management first reported a position in ADVM in Q1 2015 and held it in 25 quarters. The position peaked at $10.4M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

Rhenman & Partners Asset Management reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
Rhenman & Partners Asset Management sold 65,000 Adverum Biotechnologies shares in Q2 2021, an estimated $6.41M.
Rhenman & Partners Asset Management first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 25 quarters.
Rhenman & Partners Asset Management's Adverum Biotechnologies position peaked at $10.4M in Q2 2020.
118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.